Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CFO | March 03, 2022 | March 04, 2022 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director · Interim CFO | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date March 03, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,819 |
Ending reported balance
After 2022-03-03 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2022-03-03 · Exercise / conversion · Acquired 3,846 · Balance 29,665 Row 2 · 2022-03-03 · Exercise / conversion · Acquired 3,304 · Balance 32,969 Row 3 · 2022-03-03 · Exercise / conversion · Acquired 1,815 · Balance 34,784 Row 4 · 2022-03-03 · Sale · Disposed 3,825 · Balance 30,959 F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2022-03-03 · Sale · Disposed 2,606 · Balance 28,353 F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2022-03-03 · Sale · Disposed 1,289 · Balance 27,064 F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2022-03-03 · Sale · Disposed 858 · Balance 26,206 F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2022-03-03 · Sale · Disposed 387 · Balance 25,819 F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.34 · Expires 2023-02-23 | Direct | 0 |
Reported balance
After 2022-03-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-03 · Exercise / conversion · Disposed 3,846 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $144.67 · Expires 2024-02-22 | Direct | 3,305 |
Reported balance
After 2022-03-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-03-03 · Exercise / conversion · Disposed 3,304 · Balance 3,305 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.66 · Expires 2030-05-29 | Direct | 5,446 |
Reported balance
After 2022-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-03-03 · Exercise / conversion · Disposed 1,815 · Balance 5,446 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Fortrea Holdings Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 28,692 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 15,840 · Balance 28,692 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service. F3: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock").
F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service.
F3: This number reflects the aggregate number of RSUs held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:06 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 15,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000113 · form4.xml · derivative · entry 1 Smith David Ross · CIK 0001650274 · Director · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,692 Underlying: Common Stock · 15,840 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 20, 2026 Filed Jul 27, 2026 11:52 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 6,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000103 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Shares are the result of the settlement of Restricted Stock Units ("RSUs"), which vested on June 10, 2026 and were reported on June 12, 2026 ("Initial Form 4"). As previously reported in the Initial Form 4, an initial number of shares were withheld at settlement to satisfy tax withholding requirements on the vesting of the RSUs. The Company has issued the additional shares reported herein to the Reporting Person to true up for the actual amount of tax withholding. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:17 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 12,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000085 · form4.xml · derivative · entry 4 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,852 Underlying: Common Stock · 12,852 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F6 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F6 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F7 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:17 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000085 · form4.xml · derivative · entry 3 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F4 · derivative.exercise_date: Represents an RSU award that vested in its entirety on June 10, 2026. F4 · derivative.expiration_date: Represents an RSU award that vested in its entirety on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:17 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Tax withholdingCommon Stock | 18,244 | $16.34 | $298,106.96 |
DisclosureSEC source: 0001965040-26-000085 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,117 F2 · security: Shares withheld by Fortrea to satisfy tax withholding requirements on vesting of RSUs. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:17 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000085 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:17 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017403 · form4.xml · derivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,817 Underlying: Common Stock · 38,817 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:51 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014752 · form4.xml · derivative · entry 3 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F4 · derivative.exercise_date: Represents an RSU award that vested in its entirety on May 14, 2025. F4 · derivative.expiration_date: Represents an RSU award that vested in its entirety on May 14, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:51 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Tax withholdingCommon Stock | 2,185 | $4.78 | $10,444.30 |
DisclosureSEC source: 0001127602-25-014752 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,544 F2 · security: Shares withheld by Fortrea to satisfy tax withholding requirements on vesting of RSUs. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:51 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014752 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:24 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020752 · form4.xml · derivative · entry 3 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,282 Underlying: Common Stock · 6,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F4 · derivative.exercise_date: The RSUs vested on July 18, 2024. F4 · derivative.expiration_date: The RSUs vested on July 18, 2024. F5 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:24 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Tax withholdingCommon Stock | 1,907 | $25.85 | $49,295.95 |
DisclosureSEC source: 0001127602-24-020752 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 F2 · security: Shares withheld by Fortrea to satisfy tax withholding requirements on vesting of RSUs. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:24 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020752 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:38 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015695 · form4.xml · derivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,636 Underlying: Common Stock · 7,282 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 21:06 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-021032 · form4.xml · derivative · entry 1 Smith David Ross · CIK 0001650274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,815 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · derivative · entry 11 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,446 Underlying: Common Stock · 1,815 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,304 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · derivative · entry 10 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,305 Underlying: Common Stock · 3,304 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,846 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · derivative · entry 9 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,846 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 387 | $285.16 | $110,356.65 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 8 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,819 F5 · price: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 858 | $284.58 | $244,170.84 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,206 F4 · price: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,289 | $283.41 | $365,316.26 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,064 F3 · price: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,606 | $282.56 | $736,360.74 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,353 F2 · price: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,825 | $281.49 | $1,076,716.08 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,959 F1 · price: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,815 | $179.66 | $326,082.90 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,304 | $144.67 | $477,989.68 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,846 | $109.34 | $420,521.64 |
DisclosureSEC source: 0001127602-22-008258 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 5,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-007805 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,819 F1 · shares: Unvested restricted stock units vest as follows: 5,152 on February 28, 2023. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 23:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 374 | $289.58 | $108,302.92 |
DisclosureSEC source: 0001127602-22-006654 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,667 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 341 | $293.61 | $100,121.01 |
DisclosureSEC source: 0001127602-22-006654 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,041 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 5,364 | $312.24 | $1,674,855.36 |
DisclosureSEC source: 0001127602-22-002781 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,382 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 12,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002781 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 22, 2019. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,150 | $407.95 | $469,139.17 |
DisclosureSEC source: 0001127602-21-023436 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,425 F2 · price: This transaction was executed in multiple trades at prices ranging from $407.43 to $408.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $406.36 | $243,815.04 |
DisclosureSEC source: 0001127602-21-023436 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,575 F1 · price: This transaction was executed in multiple trades at prices ranging from $405.93 to $406.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 14:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 4,058 | $337.99 Strike: $337.99 | $1,371,563.42 |
DisclosureSEC source: 0001127602-21-018615 · form4.xml · derivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,058 Underlying: Common Stock · 4,058 shares Expires 2031-05-28 F2 · shares: Stock Options vest as follows: 1,014 on May 28, 2022, 1,015 on May 28, 2023, 1.014 on May 28, 2024 and 1,015 on May 28, 2025. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 14:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018615 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,175 F1 · shares: Unvested restricted stock units vest as follows: 328 on May 28, 2022, 328 on May 28, 2023, 328 on May 28, 2024 and 329 on May 28, 2025. Read SEC document |
| May 04, 2021 Filed May 6, 2021 17:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,305 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-21-015655 · form4.xml · derivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,609 Underlying: Common Stock · 3,305 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 17:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,305 | $340.01 | $1,123,718.18 |
DisclosureSEC source: 0001127602-21-015655 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 04, 2021 Filed May 6, 2021 17:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,305 | $144.67 | $478,134.35 |
DisclosureSEC source: 0001127602-21-015655 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,845 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-21-014394 · form4.xml · derivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,846 Underlying: Common Stock · 3,845 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,845 | $330.00 | $1,268,850.00 |
DisclosureSEC source: 0001127602-21-014394 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,845 | $109.34 | $420,412.30 |
DisclosureSEC source: 0001127602-21-014394 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 19:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,000 | $320.00 | $640,000.00 |
DisclosureSEC source: 0001127602-21-013835 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,366 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-21-008729 · form4.xml · derivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,366 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,366 | $290.12 | $1,266,646.89 |
DisclosureSEC source: 0001127602-21-008729 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,862 F1 · price: This transaction was executed in multiple trades at prices ranging from $290.00 to $290.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,366 | $88.05 | $384,426.30 |
DisclosureSEC source: 0001127602-21-008729 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 20:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 289 | $282.98 | $81,781.22 |
DisclosureSEC source: 0001127602-21-007874 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,862 Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 16:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 272 | $283.59 | $77,136.48 |
DisclosureSEC source: 0001127602-21-007205 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,031 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:19 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 242 | $283.59 | $68,628.78 |
DisclosureSEC source: 0001127602-21-007528 · form4a.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,151 F1 · shares: Due to an administrative error in the calculation of withholding taxes in the United Kingdom. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 16:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 247 | $289.55 | $71,518.85 |
DisclosureSEC source: 0001127602-21-007205 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,303 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:19 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 157 | $289.55 | $45,459.35 |
DisclosureSEC source: 0001127602-21-007528 · form4a.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,393 F1 · shares: Due to an administrative error in the calculation of withholding taxes in the United Kingdom. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.